Adalimumab ๐
๐ Patients on adalimumab should not be given any 'live' vaccines (e.g. polio, rubella, yellow fever).
โ
Inactivated vaccines are safe.
๐ About
- Fully human monoclonal anti-TNF-ฮฑ antibody.
- Assuming 26 doses per year, the annual cost of adalimumab is approximately ยฃ9,175.66.
- Always check the BNF link here.
โ๏ธ Action
- Blocks stimulation of TNF receptors โ down-regulates inflammatory response.
- Therapeutic benefit usually takes 3โ12 weeks to appear.
- Pharmacological profile is similar to infliximab.
๐ฉบ Indications
- Rheumatoid arthritis, psoriatic arthritis, severe psoriasis.
- Ankylosing spondylitis, axial spondyloarthritis.
- Crohn's disease, ulcerative colitis.
- Juvenile idiopathic arthritis.
๐ Dose
- Administered subcutaneously as a 40 mg dose every other week (RA and most indications).
- Crohnโs disease induction: 160 mg (week 0), then 80 mg (week 2). Maintenance: usually 40 mg every 2 weeks (some patients require weekly dosing).
- Must be stored in a refrigerator (2โ8 ยฐC).
| Name | Starting Dose | Frequency | Route |
| Adalimumab (RA) | 40 mg | Every 2 weeks | SC |
| Adalimumab (Crohnโs) | 160 mg (week 0), then 80 mg (week 2), then 40 mg | Every 2 weeks (ยฑ weekly if relapse) | SC |
โ ๏ธ Side Effects
- Respiratory tract infections, leukopenia, anaemia, โlipids.
- Headache, abdominal pain, nausea, vomiting.
- Elevated liver enzymes, rash, musculoskeletal pain, injection-site reactions.
- Less common but serious: demyelinating disease, lupus-like syndrome, worsening heart failure, โrisk of malignancy.
๐ซ Contraindications
- Active tuberculosis or other severe infections.
- Moderate or severe heart failure.
- Latent TB must be treated for at least 2 months before initiation.
- Do not give live vaccines during treatment; inactivated vaccines are safe.
๐ References